Skip to Late-Breaking Abstracts »
All accepted abstracts are available in the Journal for ImmunoTherapy of Cancer (JITC).
Abstract Titles
Poster Presentation Dates
All odd numbered posters will be presented on Wednesday, Nov. 11, from 5:15-5:45 p.m. EST and Friday, Nov. 13, from 4:40-5:10 p.m. EST. Even numbered posters will be presented on Thursday, Nov. 12, from 4:50-5:20 p.m. EST and Saturday, Nov. 14, from 1-1:30 p.m. EST.
Posters will be on display from 8 a.m. on Monday, Nov. 9, until the virtual poster hall closes on December 31, 2020.
| # | Type | Title | Authors | Category | Keywords |
|---|---|---|---|---|---|
| 613 | Poster Presentation | HER2-XPAT, A Novel Protease-Activatable Prodrug T Cell Engager (TCE), with Potent T-Cell Activation and Efficacy in Solid Tumors and Large Predicted Safety Margins in Non-Human Primate (NHP) | Fiore Cattaruzza, PharmD, PhD; Ayesha Nazeer; Zachary Lange; Caitlin Koski, PhD; Mikhail Hammond; Trang Dao-Pick; Angela Henkensiefken; Mika K. Derynck, MD; Volker Schellenberger, PhD; Bryan A. Irving, PhD; | Immuno-conjugates and chimeric molecules | Bispecifics; Clinical trial; Immune toxicity; Solid tumors; T cell; Targeted therapy; Tumor antigens; Tumor stroma |
| 614 | Poster Presentation | Co-stimulation via PD1-41BB chimeric switch receptor enhances function of TCR-T cells in an immune-suppressive milieu and under chronic antigen stimulation | Melanie Salvermoser; Maria Gerget; Franziska Hasselmann; Elfriede Noessner, Prof. Dr.; Christian Ellinger, Dr. Rer. Nat.; Monika Braun; Dolores J. Schendel, PhD; Daniel Sommermeyer, PhD; Nadja Sailer, Dr. rer. nat.; | Immuno-conjugates and chimeric molecules | Adoptive immunotherapy; Checkpoint blockade; Costimulation; Solid tumors; T cell; Tumor microenvironment |
| 615 | Poster Presentation | Targeted Immune Cell Activation by Systemic Delivery of Toll-Like Receptor 9 Agonist Antibody Conjugates Induce Potent Anti-Tumor Immunity | Ons Harrabi, BA; Amy Chen; Emma Sangalang; Laura Doyle; Danielle Fontaine; Bora Han, PhD; Curt W. Bradshaw, PhD; Jaume Pons, PhD; Janet Sim, PhD; Tracy C. Kuo, PhD; Hong I. Wan, PhD; | Immuno-conjugates and chimeric molecules | Antibody; Antigen presenting cells; B cell; Dendritic cell; Myeloid cells; TLR |
| 616 | Poster Presentation | A novel non-covalent linker peptide with nanomolar affinity for clinical IgG1 antibodies preserves antibody-antigen affinity and drug potency against PDL1+ melanoma when conjugated with DM1 | John T. Butterfield, BS; Shari L. Sutor, BS; Wendy K. Nevala, MS; Svetomir N. Markovic, MD, PhD; | Immuno-conjugates and chimeric molecules | Antibody; Chemotherapy; Targeted therapy |
| 617 | Poster Presentation | Tisotumab vedotin shows immunomodulatory activity through induction of immunogenic cell death | Elizabeth Gray, PhD; Kelly Hensley; Sean Allred; Esther Trueblood; John Gosink; Robert Thurman; Kaleb Smith; Celine Jacquemont, PhD; Mark Bieda; Jason Gow; Jeffrey R. Harris; Lauren K. Brady; Ibrahima Soumaoro; Shweta Jain; Leonardo Nicacio; Shyra J. Gardai, PhD; | Immuno-conjugates and chimeric molecules | Antibody; Antigen presenting cells; Solid tumors; Tumor microenvironment |
| 618 | Poster Presentation | Vedotin ADCs induce ER stress and elicit hallmarks of ICD across multiple cancer indications | Kerry Klussman, B.S.; Elena-Marie Tenn; Shaylin Higgins; Rebecca Mazahreh; Katie Snead; Joseph Z. Hamilton; Bryan M. Grogan, MS; Johann Sigurjonsson; Anthony Cao; Shyra J. Gardai, PhD; Bernard A. Liu; | Immuno-conjugates and chimeric molecules | Antibody; Antigen presenting cells; Targeted therapy |
| 619 | Poster Presentation | Evaluating the effectiveness of targeted ADC therapy in a patient-derived ex vivo tumoroid model, 3D-EX, for quantitative tumor cell killing | Jenny Kreahling, PhD; Jared C. Ehrhart, PhD; Mibel Pabon, PhD; Stephen Iwanowycz, PhD; Tina Pastoor; Soner Altiok, MD, PhD; | Immuno-conjugates and chimeric molecules | Antibody; Checkpoint blockade; Cytokine; Gene expression; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 620 | Poster Presentation | Tumor cell-intrinsic STING pathway is activated in the presence of cues from immune cells and contributes to the anti-tumor activity of tumor cell-targeted STING agonist antibody-drug conjugates | Naniye Malli Cetinbas, PhD; Travis Monnell; Winnie Lee; Kalli C. Catcott, PhD; Chen-Ni Chin, PhD; Pamela Shaw; Kelly Slocum; LiuLiang Qin; Kenneth Avocetien; Keith Bentley, PhD; Susan Clardy, PhD; Brian Jones, PhD; Eugene Kelleher; Joshua D. Thomas; Rebecca Mosher, MD; Dorin Toader, PhD; Jeremy Duvall, PhD; Raghida A. Bukhalid, PhD; Marc Damelin, PhD; Timothy B. Lowinger, PhD; | Immuno-conjugates and chimeric molecules | Chemokine; Cytokine; Monocyte/Macrophage; Myeloid cells; Targeted therapy; Tumor microenvironment |
| 621 | Poster Presentation | A Tregs depleting, CD25-targeted antibody-drug conjugate synergizes with tumor-targeted radiotherapy and systemic interleukin-2 in pre-clinical models of solid cancers | Patrick H. van Berkel, Ph.D; Francesca Zammarchi, PhD; Francesca Zammarchi, PhD; | Immuno-conjugates and chimeric molecules | Antibody; Radiotherapy; Regulatory T cell (Treg cell); Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| 622 | Poster Presentation | PD-L1 is a potential predictive biomarker for response to RM-1929 treatment in recurrent head and neck squamous cell carcinoma patients | C. Daniel De Magalhaes Filho; Chung-Wein Lee; Nikolai Suslov; Jerry Fong, PhD; Miguel Garcia-Guzman; | Immuno-conjugates and chimeric molecules | Antibody; Biomarkers; Checkpoint blockade; Solid tumors; Targeted therapy |
| 623 | Poster Presentation | Immuno-STATs: Leveraging protein engineering to expand and track antigen-specific T cells in vivo | Stad H. Zeigler; Andrew W. Woodham, PhD; Mengyan Li, PhD; Ella L. Zeyang, PhD; Stephen C. Kolifrath; Mohammad Rashidian, PhD; Kaitlyn E. O’Connor; Rodolfo J. Chaparro, PhD; Ronald D. Seidel, PhD; Maia Mesyngier; Ross W. Cheloha, PhD; Jason L. Dearling, PhD; Phaneendra K. Duddempudi, PhD; Alev Celikgil, MD; Scott J. Garforth, PhD; Alan Packard, PhD; Harris Goldstein, MD; Hidde L. Ploegh, PhD; Steven C. Almo, PhD; | Immuno-conjugates and chimeric molecules | Bispecifics; Costimulation; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 624 | Poster Presentation | IFNγ secreted by tebentafusp (IMCgp100)-redirected T cells inhibits expression of melanin synthesis pathway genes in healthy melanocytes | Mariantonella Vardeu, PhD; David Depoil, PhD; Camille Britton-Rivet, PhD; Jane Houghton; Jane Harper, PhD; Gabrielle Le Provost, PhD; Laura Collins, PhD; Koustubh Ranade, PhD; Adel Benlahrech, PhD; | Immuno-conjugates and chimeric molecules | Bispecifics; T cell; Targeted therapy |
| 625 | Poster Presentation | Bispecific Personalized Aptamer for the Treatment of Solid Tumors | Erez Lavi; Nir Skalka; Neta Zilony Hanin; Zohar Pode; Anastasia Paz; Yeela Scharff; Neria Reiss; Omer Levy; Elinor Debby; Liron Levy- Efrati; Vitaliy Buravenkov; Itay Liron; Yaniv Amir; Raanan Berger, MD; Ido Bachelet; Guy Neev; Irit Carmi Levy, PhD; | Immuno-conjugates and chimeric molecules | Bispecifics; Solid tumors; Targeted therapy |
| 626 | Poster Presentation | Improving the yeast transformation efficiency for yeast display in antibody development | Jian Chen, PhD; George Sun; Jian Chen, PhD; | Immuno-conjugates and chimeric molecules | Antibody |
| 628 | Poster Presentation | IL-2 augments ImmTAC-dependent T cell activation and tumour cell killing | Duncan M. Gascoyne, PhD; Kristina Petrovic, PhD; Koustubh Ranade, PhD; David Depoil, PhD; | Immuno-conjugates and chimeric molecules | Bispecifics; Cytokine; T cell; Targeted therapy |
| 630 | Poster Presentation | PD-L1/CD47 tumor directed B-BodyTM bispecific antibodies demonstrating significant anti-tumor activity with no toxicity in preclinical models | Seema Kantak, PhD, MS, M.Sc.; Bryan Glaser, PhD; Justin Wetter; Bee-Cheng Sim; Jeff Higaki; Jacob Beal; Sara Ollerman; Dileep Pulukkunat; Mandar Bawadekar; Charles Kaplan; Peter Lamb; Bonnie Hammer; | Immuno-conjugates and chimeric molecules | Antibody; Bispecifics; Checkpoint blockade |
| 631 | Poster Presentation | Development of highly efficacious and safe targeted cancer immunotherapy via IL12-based TMEkine™ platform | Dahea Lee; Donggeon Kim, DVM,PhD; Soomin Ryu; Byoung Chul Lee, PhD; | Immuno-conjugates and chimeric molecules | Antibody; Bispecifics; Cytokine; Leukemia/Lymphoma; Targeted therapy; Tumor antigens; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 632 | Oral Presentation | HPN601 is a protease-activated EpCAM-targeting T cell engager with an improved safety profile for the treatment of solid tumors | Jack Lin, Ph.D.; Sony S. Rocha; Kathryn Kwant, Ph.D.; Maria R. Dayao; Tessie M. Ng, Ph.D.; Wade Aaron, BS; Evan Callihan; Maria Gamez-Guerrero; Golzar Hemmati; Kevin J. Wright, Ph.D.; Manasi Barath; Yinghua Xiao, Master Degree; Timothy Yu; Patrick Chew; Thomas Evans; Jessica O'Rear; Scott Gatto; Michael Cremin; Stephen Yu; Purbasa Patnaik; Avneel Hundal; Richard Austin, Ph.D.; Bryan Lemon, Ph.D.; Holger Wesche, Ph.D.; | Immuno-conjugates and chimeric molecules | Antibody; Bispecifics; Immune toxicity; Solid tumors; T cell; Targeted therapy; Tumor antigens; Tumor microenvironment; Tumor stroma |
| 633 | Oral Presentation | Dual-targeting of 4-1BB and OX40 with an ADAPTIR™ bispecific antibody enhances anti-tumor responses to solid tumor | Michelle Nelson; Robert Miller; Gabriele Blahnik-Fagan; Lauren Loh; Danielle Van Citters; Lynda Misher; Megan Sprague; Maria Dasovich; Irene Barber; Kathy Maggiora; Franz Gruswitz; Brian Woodruff; Kelsey Huntington; Aelish Guinn; Megan Aguilar; Mollie Daugherty; Elizabeth Haglin; Jane Gross; Peter Pavlik; Catherine McMahan; David Bienvenue; Gabriela Hernandez-Hoyos, PhD; | Immuno-conjugates and chimeric molecules | Antibody; Bispecifics; Costimulation; NK/NK T cell; T cell |
| 634 | Poster Presentation | Production and testing of a novel bispecific nanobody construct targeting NK cells and EGFR expressing malignancies | Elisa C. Toffoli, MD; Abdolkarim Sheikhi; Roeland Lameris; Lisa A. King; Jurriaan Tuynman; Jan Spanholtz; Henk Verheul; Tanja D. de Gruijl, PhD; Hans J. Van der Vliet, MD, PhD; Elisa C. Toffoli, MD; | Immuno-conjugates and chimeric molecules | Antibody; Bispecifics; NK/NK T cell |
| 635 | Poster Presentation | A novel site-directed chemical conjugation technology confers antitumor activity via native Fc receptor to plasma immunoglobulin by attaching tumor binders | Christian M. Vidal, PhD; Michael Cukan, PhD; Rajat Varma, PhD; Lawrence Iben, MA; Tanya Berbasova, PhD; Ada Vaill, MS; Anna Bunin, PhD; Ann Marie Rossi, MS; David Trinh, BS; Katy McGrath, BS; Enrique Alvarez, DVM; Matthew Welsch, PhD; Luca Rastelli, PhD; | Immuno-conjugates and chimeric molecules | Antibody; B cell; Leukemia/Lymphoma; Monocyte/Macrophage; NK/NK T cell; Targeted therapy; Tumor antigens |
